CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in the prevalence of obesity
3.4.1.2. Increase in number of drugs in pipeline
3.4.1.3. Increase in number of clinical trials
3.4.2. Restraints
3.4.2.1. Potential side effects of anti-obesity drugs
3.4.3. Opportunities
3.4.3.1. High growth potential in developing economies
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Prescription Drugs
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Over The Counter Drugs
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
CHAPTER 5: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION
5.1. Overview
5.1.1. Market size and forecast
5.2. Centrally Acting Anti-Obesity Drugs
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Peripherally Acting Anti-Obesity Drugs
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Oral Route
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Subcutaneous Route
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
CHAPTER 7: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL
7.1. Overview
7.1.1. Market size and forecast
7.2. Hospital Pharmacies
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis by country
7.3. Retail Pharmacies
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market share analysis by country
7.4. Online Pharmacies
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by region
7.4.3. Market share analysis by country
CHAPTER 8: ANTI-OBESITY DRUGS MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast By Region
8.2. North America
8.2.1. Key trends and opportunities
8.2.2. Market size and forecast, by Drug Type
8.2.3. Market size and forecast, by Mechanism of Action
8.2.4. Market size and forecast, by Route of Administration
8.2.5. Market size and forecast, by Distribution Channel
8.2.6. Market size and forecast, by country
8.2.6.1. U.S.
8.2.6.1.1. Key market trends, growth factors and opportunities
8.2.6.1.2. Market size and forecast, by Drug Type
8.2.6.1.3. Market size and forecast, by Mechanism of Action
8.2.6.1.4. Market size and forecast, by Route of Administration
8.2.6.1.5. Market size and forecast, by Distribution Channel
8.2.6.2. Canada
8.2.6.2.1. Key market trends, growth factors and opportunities
8.2.6.2.2. Market size and forecast, by Drug Type
8.2.6.2.3. Market size and forecast, by Mechanism of Action
8.2.6.2.4. Market size and forecast, by Route of Administration
8.2.6.2.5. Market size and forecast, by Distribution Channel
8.2.6.3. Mexico
8.2.6.3.1. Key market trends, growth factors and opportunities
8.2.6.3.2. Market size and forecast, by Drug Type
8.2.6.3.3. Market size and forecast, by Mechanism of Action
8.2.6.3.4. Market size and forecast, by Route of Administration
8.2.6.3.5. Market size and forecast, by Distribution Channel
8.3. Europe
8.3.1. Key trends and opportunities
8.3.2. Market size and forecast, by Drug Type
8.3.3. Market size and forecast, by Mechanism of Action
8.3.4. Market size and forecast, by Route of Administration
8.3.5. Market size and forecast, by Distribution Channel
8.3.6. Market size and forecast, by country
8.3.6.1. Germany
8.3.6.1.1. Key market trends, growth factors and opportunities
8.3.6.1.2. Market size and forecast, by Drug Type
8.3.6.1.3. Market size and forecast, by Mechanism of Action
8.3.6.1.4. Market size and forecast, by Route of Administration
8.3.6.1.5. Market size and forecast, by Distribution Channel
8.3.6.2. France
8.3.6.2.1. Key market trends, growth factors and opportunities
8.3.6.2.2. Market size and forecast, by Drug Type
8.3.6.2.3. Market size and forecast, by Mechanism of Action
8.3.6.2.4. Market size and forecast, by Route of Administration
8.3.6.2.5. Market size and forecast, by Distribution Channel
8.3.6.3. UK
8.3.6.3.1. Key market trends, growth factors and opportunities
8.3.6.3.2. Market size and forecast, by Drug Type
8.3.6.3.3. Market size and forecast, by Mechanism of Action
8.3.6.3.4. Market size and forecast, by Route of Administration
8.3.6.3.5. Market size and forecast, by Distribution Channel
8.3.6.4. Italy
8.3.6.4.1. Key market trends, growth factors and opportunities
8.3.6.4.2. Market size and forecast, by Drug Type
8.3.6.4.3. Market size and forecast, by Mechanism of Action
8.3.6.4.4. Market size and forecast, by Route of Administration
8.3.6.4.5. Market size and forecast, by Distribution Channel
8.3.6.5. Spain
8.3.6.5.1. Key market trends, growth factors and opportunities
8.3.6.5.2. Market size and forecast, by Drug Type
8.3.6.5.3. Market size and forecast, by Mechanism of Action
8.3.6.5.4. Market size and forecast, by Route of Administration
8.3.6.5.5. Market size and forecast, by Distribution Channel
8.3.6.6. Rest of Europe
8.3.6.6.1. Key market trends, growth factors and opportunities
8.3.6.6.2. Market size and forecast, by Drug Type
8.3.6.6.3. Market size and forecast, by Mechanism of Action
8.3.6.6.4. Market size and forecast, by Route of Administration
8.3.6.6.5. Market size and forecast, by Distribution Channel
8.4. Asia-Pacific
8.4.1. Key trends and opportunities
8.4.2. Market size and forecast, by Drug Type
8.4.3. Market size and forecast, by Mechanism of Action
8.4.4. Market size and forecast, by Route of Administration
8.4.5. Market size and forecast, by Distribution Channel
8.4.6. Market size and forecast, by country
8.4.6.1. Japan
8.4.6.1.1. Key market trends, growth factors and opportunities
8.4.6.1.2. Market size and forecast, by Drug Type
8.4.6.1.3. Market size and forecast, by Mechanism of Action
8.4.6.1.4. Market size and forecast, by Route of Administration
8.4.6.1.5. Market size and forecast, by Distribution Channel
8.4.6.2. China
8.4.6.2.1. Key market trends, growth factors and opportunities
8.4.6.2.2. Market size and forecast, by Drug Type
8.4.6.2.3. Market size and forecast, by Mechanism of Action
8.4.6.2.4. Market size and forecast, by Route of Administration
8.4.6.2.5. Market size and forecast, by Distribution Channel
8.4.6.3. Australia
8.4.6.3.1. Key market trends, growth factors and opportunities
8.4.6.3.2. Market size and forecast, by Drug Type
8.4.6.3.3. Market size and forecast, by Mechanism of Action
8.4.6.3.4. Market size and forecast, by Route of Administration
8.4.6.3.5. Market size and forecast, by Distribution Channel
8.4.6.4. India
8.4.6.4.1. Key market trends, growth factors and opportunities
8.4.6.4.2. Market size and forecast, by Drug Type
8.4.6.4.3. Market size and forecast, by Mechanism of Action
8.4.6.4.4. Market size and forecast, by Route of Administration
8.4.6.4.5. Market size and forecast, by Distribution Channel
8.4.6.5. South Korea
8.4.6.5.1. Key market trends, growth factors and opportunities
8.4.6.5.2. Market size and forecast, by Drug Type
8.4.6.5.3. Market size and forecast, by Mechanism of Action
8.4.6.5.4. Market size and forecast, by Route of Administration
8.4.6.5.5. Market size and forecast, by Distribution Channel
8.4.6.6. Rest of Asia-Pacific
8.4.6.6.1. Key market trends, growth factors and opportunities
8.4.6.6.2. Market size and forecast, by Drug Type
8.4.6.6.3. Market size and forecast, by Mechanism of Action
8.4.6.6.4. Market size and forecast, by Route of Administration
8.4.6.6.5. Market size and forecast, by Distribution Channel
8.5. LAMEA
8.5.1. Key trends and opportunities
8.5.2. Market size and forecast, by Drug Type
8.5.3. Market size and forecast, by Mechanism of Action
8.5.4. Market size and forecast, by Route of Administration
8.5.5. Market size and forecast, by Distribution Channel
8.5.6. Market size and forecast, by country
8.5.6.1. Brazil
8.5.6.1.1. Key market trends, growth factors and opportunities
8.5.6.1.2. Market size and forecast, by Drug Type
8.5.6.1.3. Market size and forecast, by Mechanism of Action
8.5.6.1.4. Market size and forecast, by Route of Administration
8.5.6.1.5. Market size and forecast, by Distribution Channel
8.5.6.2. Saudi Arabia
8.5.6.2.1. Key market trends, growth factors and opportunities
8.5.6.2.2. Market size and forecast, by Drug Type
8.5.6.2.3. Market size and forecast, by Mechanism of Action
8.5.6.2.4. Market size and forecast, by Route of Administration
8.5.6.2.5. Market size and forecast, by Distribution Channel
8.5.6.3. South Africa
8.5.6.3.1. Key market trends, growth factors and opportunities
8.5.6.3.2. Market size and forecast, by Drug Type
8.5.6.3.3. Market size and forecast, by Mechanism of Action
8.5.6.3.4. Market size and forecast, by Route of Administration
8.5.6.3.5. Market size and forecast, by Distribution Channel
8.5.6.4. Rest of LAMEA
8.5.6.4.1. Key market trends, growth factors and opportunities
8.5.6.4.2. Market size and forecast, by Drug Type
8.5.6.4.3. Market size and forecast, by Mechanism of Action
8.5.6.4.4. Market size and forecast, by Route of Administration
8.5.6.4.5. Market size and forecast, by Distribution Channel
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top player positioning, 2022
CHAPTER 10: COMPANY PROFILES
10.1. Currax Pharmaceuticals LLC
10.1.1. Company overview
10.1.2. Key Executives
10.1.3. Company snapshot
10.1.4. Operating business segments
10.1.5. Product portfolio
10.1.6. Key strategic moves and developments
10.2. KVK Tech Inc.
10.2.1. Company overview
10.2.2. Key Executives
10.2.3. Company snapshot
10.2.4. Operating business segments
10.2.5. Product portfolio
10.3. Gelesis Holdings, INC.
10.3.1. Company overview
10.3.2. Key Executives
10.3.3. Company snapshot
10.3.4. Operating business segments
10.3.5. Product portfolio
10.3.6. Business performance
10.3.7. Key strategic moves and developments
10.4. Vivus LLC.
10.4.1. Company overview
10.4.2. Key Executives
10.4.3. Company snapshot
10.4.4. Operating business segments
10.4.5. Product portfolio
10.4.6. Key strategic moves and developments
10.5. CHEPLAPHARM Arzneimittel GmbH
10.5.1. Company overview
10.5.2. Key Executives
10.5.3. Company snapshot
10.5.4. Operating business segments
10.5.5. Product portfolio
10.6. Pfizer Inc.
10.6.1. Company overview
10.6.2. Key Executives
10.6.3. Company snapshot
10.6.4. Operating business segments
10.6.5. Product portfolio
10.6.6. Business performance
10.7. Rhythm Pharmaceuticals
10.7.1. Company overview
10.7.2. Key Executives
10.7.3. Company snapshot
10.7.4. Operating business segments
10.7.5. Product portfolio
10.7.6. Business performance
10.7.7. Key strategic moves and developments
10.8. Novo Nordisk A/S
10.8.1. Company overview
10.8.2. Key Executives
10.8.3. Company snapshot
10.8.4. Operating business segments
10.8.5. Product portfolio
10.8.6. Business performance
10.8.7. Key strategic moves and developments
10.9. GlaxoSmithKline plc
10.9.1. Company overview
10.9.2. Key Executives
10.9.3. Company snapshot
10.9.4. Operating business segments
10.9.5. Product portfolio
10.9.6. Business performance
10.10. Boehringer Ingelheim International GmbH
10.10.1. Company overview
10.10.2. Key Executives
10.10.3. Company snapshot
10.10.4. Operating business segments
10.10.5. Product portfolio
10.10.6. Business performance
10.10.7. Key strategic moves and developments
TABLE 01. GLOBAL ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 02. ANTI-OBESITY DRUGS MARKET FOR PRESCRIPTION DRUGS, BY REGION, 2022-2032 ($MILLION)
TABLE 03. ANTI-OBESITY DRUGS MARKET FOR OVER THE COUNTER DRUGS, BY REGION, 2022-2032 ($MILLION)
TABLE 04. GLOBAL ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 05. ANTI-OBESITY DRUGS MARKET FOR CENTRALLY ACTING ANTI-OBESITY DRUGS, BY REGION, 2022-2032 ($MILLION)
TABLE 06. ANTI-OBESITY DRUGS MARKET FOR PERIPHERALLY ACTING ANTI-OBESITY DRUGS, BY REGION, 2022-2032 ($MILLION)
TABLE 07. GLOBAL ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 08. ANTI-OBESITY DRUGS MARKET FOR ORAL ROUTE, BY REGION, 2022-2032 ($MILLION)
TABLE 09. ANTI-OBESITY DRUGS MARKET FOR SUBCUTANEOUS ROUTE, BY REGION, 2022-2032 ($MILLION)
TABLE 10. GLOBAL ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 11. ANTI-OBESITY DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 12. ANTI-OBESITY DRUGS MARKET FOR RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 13. ANTI-OBESITY DRUGS MARKET FOR ONLINE PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 14. ANTI-OBESITY DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 15. NORTH AMERICA ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 17. NORTH AMERICA ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 18. NORTH AMERICA ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 19. NORTH AMERICA ANTI-OBESITY DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 20. U.S. ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 21. U.S. ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 22. U.S. ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 23. U.S. ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 24. CANADA ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 25. CANADA ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 26. CANADA ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 27. CANADA ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 28. MEXICO ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 29. MEXICO ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 30. MEXICO ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 31. MEXICO ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 32. EUROPE ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 33. EUROPE ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 34. EUROPE ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 35. EUROPE ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 36. EUROPE ANTI-OBESITY DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 37. GERMANY ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 38. GERMANY ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 39. GERMANY ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 40. GERMANY ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 41. FRANCE ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 42. FRANCE ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 43. FRANCE ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 44. FRANCE ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 45. UK ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 46. UK ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 47. UK ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 48. UK ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 49. ITALY ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 50. ITALY ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 51. ITALY ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 52. ITALY ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 53. SPAIN ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 54. SPAIN ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 55. SPAIN ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 56. SPAIN ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 57. REST OF EUROPE ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 58. REST OF EUROPE ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 59. REST OF EUROPE ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 60. REST OF EUROPE ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 61. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 62. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 63. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 64. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 65. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 66. JAPAN ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 67. JAPAN ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 68. JAPAN ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 69. JAPAN ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 70. CHINA ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 71. CHINA ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 72. CHINA ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 73. CHINA ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 74. AUSTRALIA ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 75. AUSTRALIA ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 76. AUSTRALIA ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 77. AUSTRALIA ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 78. INDIA ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 79. INDIA ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 80. INDIA ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 81. INDIA ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 82. SOUTH KOREA ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 83. SOUTH KOREA ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 84. SOUTH KOREA ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 85. SOUTH KOREA ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 86. REST OF ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 87. REST OF ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 88. REST OF ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 89. REST OF ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 90. LAMEA ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 91. LAMEA ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 92. LAMEA ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 93. LAMEA ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 94. LAMEA ANTI-OBESITY DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 95. BRAZIL ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 96. BRAZIL ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 97. BRAZIL ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 98. BRAZIL ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 99. SAUDI ARABIA ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 100. SAUDI ARABIA ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 101. SAUDI ARABIA ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 102. SAUDI ARABIA ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 103. SOUTH AFRICA ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 104. SOUTH AFRICA ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 105. SOUTH AFRICA ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 106. SOUTH AFRICA ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 107. REST OF LAMEA ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 108. REST OF LAMEA ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 109. REST OF LAMEA ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 110. REST OF LAMEA ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 111. CURRAX PHARMACEUTICALS LLC: KEY EXECUTIVES
TABLE 112. CURRAX PHARMACEUTICALS LLC: COMPANY SNAPSHOT
TABLE 113. CURRAX PHARMACEUTICALS LLC: PRODUCT SEGMENTS
TABLE 114. CURRAX PHARMACEUTICALS LLC: PRODUCT PORTFOLIO
TABLE 115. CURRAX PHARMACEUTICALS LLC: KEY STRATERGIES
TABLE 116. KVK TECH INC.: KEY EXECUTIVES
TABLE 117. KVK TECH INC.: COMPANY SNAPSHOT
TABLE 118. KVK TECH INC.: PRODUCT SEGMENTS
TABLE 119. KVK TECH INC.: SERVICE SEGMENTS
TABLE 120. KVK TECH INC.: PRODUCT PORTFOLIO
TABLE 121. GELESIS HOLDINGS, INC.: KEY EXECUTIVES
TABLE 122. GELESIS HOLDINGS, INC.: COMPANY SNAPSHOT
TABLE 123. GELESIS HOLDINGS, INC.: SERVICE SEGMENTS
TABLE 124. GELESIS HOLDINGS, INC.: PRODUCT PORTFOLIO
TABLE 125. GELESIS HOLDINGS, INC.: KEY STRATERGIES
TABLE 126. VIVUS LLC.: KEY EXECUTIVES
TABLE 127. VIVUS LLC.: COMPANY SNAPSHOT
TABLE 128. VIVUS LLC.: PRODUCT SEGMENTS
TABLE 129. VIVUS LLC.: SERVICE SEGMENTS
TABLE 130. VIVUS LLC.: PRODUCT PORTFOLIO
TABLE 131. VIVUS LLC.: KEY STRATERGIES
TABLE 132. CHEPLAPHARM ARZNEIMITTEL GMBH: KEY EXECUTIVES
TABLE 133. CHEPLAPHARM ARZNEIMITTEL GMBH: COMPANY SNAPSHOT
TABLE 134. CHEPLAPHARM ARZNEIMITTEL GMBH: SERVICE SEGMENTS
TABLE 135. CHEPLAPHARM ARZNEIMITTEL GMBH: PRODUCT PORTFOLIO
TABLE 136. PFIZER INC.: KEY EXECUTIVES
TABLE 137. PFIZER INC.: COMPANY SNAPSHOT
TABLE 138. PFIZER INC.: PRODUCT SEGMENTS
TABLE 139. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 140. RHYTHM PHARMACEUTICALS: KEY EXECUTIVES
TABLE 141. RHYTHM PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 142. RHYTHM PHARMACEUTICALS: SERVICE SEGMENTS
TABLE 143. RHYTHM PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 144. RHYTHM PHARMACEUTICALS: KEY STRATERGIES
TABLE 145. NOVO NORDISK A/S: KEY EXECUTIVES
TABLE 146. NOVO NORDISK A/S: COMPANY SNAPSHOT
TABLE 147. NOVO NORDISK A/S: PRODUCT SEGMENTS
TABLE 148. NOVO NORDISK A/S: PRODUCT PORTFOLIO
TABLE 149. NOVO NORDISK A/S: KEY STRATERGIES
TABLE 150. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
TABLE 151. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 152. GLAXOSMITHKLINE PLC: PRODUCT SEGMENTS
TABLE 153. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 154. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY EXECUTIVES
TABLE 155. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT
TABLE 156. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT SEGMENTS
TABLE 157. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT PORTFOLIO
TABLE 158. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY STRATERGIES
